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Abstract
Modern biomedical and genetic studies require large study cohorts; blood donors have been suggested to represent an
appropriate group for recruiting healthy cohorts. The Blood Service Biobank (BSB) in Finland was recently established to
recruit blood donors willing to give broad biobank consent. The aim of the present study is to understand how the blood
bank context inﬂuences views on donating samples and health data. We organised 61 interviews and 10 group discussions
with current and potential blood donors. Using qualitative content analysis, we identiﬁed three discussion frameworks that
summarise the results. We found that frequent blood donors associated the voluntary act of donation with caring for patients.
The blood donation experience was considered to accommodate biobank participation, but also allowed critical observations
on the integration of research data collection into blood donation. Research participants identiﬁed an important difference
between the blood bank and biobank contexts. In the biobank context, the focus shifts from donating blood to patients into
donating personal and genetic data for research use. Blood donors’ anxiety over data use was balanced with their experience
of the trustworthiness of the Blood Service. These experiences indicated that the new biobanking activity could be trusted to
a familiar organisation. To build donors’ trust, biobanks should invest in their institutional reputation, donor experience and
dialogue with donors. These ﬁndings can be applied to other institutions that are considering setting up biobanks with broad
consent for personal data use.
Introduction
Modern biomedical and genetic studies require large study
cohorts that may be collected in biobanks with broad con-
sent for sample and data use. Biobanks have different forms
not only depending on the samples and data they collect, but
also regarding their institutional context and recruitment of
donors. Hospital biobanks primarily collect samples and
health records from their patients, whereas population or
epidemiological cohorts aim to collect representative sam-
ples of the entire population. It has been suggested, and
there are good examples to support this, that blood donors
would constitute a good cohort representing healthy popu-
lations [1]. Integration of a biobank into a traditional blood
bank has advantages. The existing blood collection infra-
structure and pool of blood donors can be effectively uti-
lised for research purposes. For researchers, a blood donor
biobank offers access to a longitudinal collection of samples
in addition to genetic and health data [2]. Blood donors
have, furthermore, been reported to have higher than aver-
age willingness to participate in biobanks [3] and to approve
genetic research [4]. Indeed, some blood donor biobanks
have been very successful in recruiting blood donors [2, 5].
To understand why this is so, we studied the views of
current blood donors and potential donors on biobanking
and use of their samples and data for research and analysed
how they regarded such activities in comparison with the
standard blood donation to patients. Our aim was to
understand whether the blood bank context has particular
characteristics related to biobank participation. The biobank
in the present study was the Blood Service Biobank (BSB),
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operated as part of the Finnish Red Cross (FRC) Blood
Service, the only blood establishment in Finland. At
the time of the collection of focus group data in spring
2017, the FRC Blood Service was planning to establish
its own biobank, a plan which was implemented in
November 2017.
Biobank activities in Finland are regulated by the Bio-
bank Act (688/2012). The Act provides a framework for the
utilisation of human biological samples and data in future
medical research and product development, while securing
rights of biobank research participants [6]. The Act deﬁnes
criteria of a biobank and states that all biobanks must be
registered. To register a biobank, the organisation must have
permits from the ethical evaluation authority (TUKIJA) and
from the National Supervisory Authority (Valvira) [7].
Currently, the BSB is one of the 10 registered biobanks in
Finland. The national regulation dictates the basis for bio-
banking practices [7]. According to the Act, all biobank
research is based on broad consent. The Act gives biobank
participants the right to withdraw their consent and to
request from the biobank information on the use of their
samples and the clinical signiﬁcance of obtained health
information. The use of information is limited, excluding
certain purposes and de-identiﬁcation policies are imposed
[6]. With the encompassing national biobank regulation in
place, the May 2018 General Data Protection Regulation
(GDPR) has so far not resulted on changes for biobanking
and participant rights. For example, the BSB need not
change the information on biobank consent for blood
donors after the GDPR. Surveys from Finland report a
comparatively relaxed public attitude to the broad consent
[8] and positive outlook on biobanks [9]. A recent survey,
however, found that majority felt their knowledge on bio-
banks was still insufﬁcient [10]. The Blood Service Biobank
began recruiting blood donors for biobanking at blood
donation sites on November 2017; all focus groups took
place before the BSB launch. Nurses inform blood donors
of the opportunity to give the broad consent and an aliquot
of blood for research. In our previous study [11], we found
that Finnish blood donors were willing to donate blood also
to scientiﬁc research in addition to a standard blood dona-
tion. Contributing to research was considered to align with
blood donors’ motives of helping patients and contributing
to common good. For the interviewees, the concrete link to
patients who need blood and the ease of familiar blood
donation practice was important.
In the present study, our focus is on understanding how
current and potential blood donors perceive the BSB in the
context of blood donation. This study was done before the
launch of the BSB, so our questions are prospective in
nature. Previous studies on biobank participation show
these decisions to be very much dependent on donor’s
perception of the social context [12]. How a potential
biobank participant interprets this context—i.e., who is
asking for donation and how, and what are the institutions
and risks involved—can inﬂuence the decision more than
formal legal and technical information on biobanks
[8, 13, 14]. In our case, biobank participation was assumed
to take place in the context of the FRC Blood Service that
has a long tradition in blood procurement from voluntary
donors. A success of any blood bank depends not only on
its physical infrastructure but also how well the message it
promotes facilitates donations [15]. The BSB’s slogan “A
new dimension to extend your help” [16] can be seen as an
example of such message that promotes a donor perception
in which donating blood to biobank represents a continuum
of standard blood donation. Considering the increasingly
complex systems procuring blood, deciding for or against
different donation purpose can be challenging [17]. Use of
qualitative methods provided us with a valuable means of
analysing what arguments make participation sensible and
appropriate from blood donors point of view. We see that




Our research data consist of 61 blood donor interviews
ranging from 10 to 30 min and 10 focus groups discussions
that were approximately 1.5 h long each. The interviewees
were organised at seven different blood donation sites to
capture a sufﬁcient range of viewpoints. More information
on the interviewees and interview recruitment processes is
provided in Supplementary material (Tables S1 and S2).
Ten focus groups (Table 1) were formed from university
science students (FG 1–2), Finnish Defence Force privates
(FG 3–4), frequent blood donors (FG 5–6) and participants
of the GeneRISK study (FG 7–10). The organisation of the
focus groups was based on the following objectives: groups
that represent different stages of experience on blood
donation (none—frequent) with focus on younger age
groups and on blood donors who already had participated in
a genetic study through the Blood Service (GeneRISK). We
wanted to include a group of non-blood donors and mixed
groups of donors and non-donors to the data composed of
discussions with frequent blood donors. The idea was to
observe (1) what views were generally shared among all
participants; and (2) how practical experience from the
Blood Service was reﬂected on views. The GeneRISK study
was conducted in the Blood Service among interested blood
donors from the age group of 45–60. The GeneRISK study
subjects (www.generisk.ﬁ) received information on their
genetic and lifestyle related risks of cardiovascular diseases.
1660 V. Raivola et al.
These participants are different from the other groups as
they had signed a consent for the THL Biobank as part of
the GeneRISK study protocol.
Data collection
Open-ended interviews were conducted by V.R. and the
discussions groups were moderated by V.R. or K.S. Ques-
tions for both interviews and focus groups covered four
themes in the following sequence: (A) donating blood for
patients, (B) donating blood and information for research
and (C) participation to the BSB, and (D) the possibility to
return genetic risk or health data to donors. Description of
interview questions topics can be found in Supplement S3.
Data collection continued until the accumulation of view-
points was observed to reach saturation, thereafter addi-
tional interviews were likely to have only a modest increase
in the qualitative variety of the data, i.e., topics raised. All
discussions were recorded. The two methods of data col-
lection were combined to capture a broader variance in
content and reasoning. The blood donor interviews pro-
vided a more structured outlook than the range of available
accounts. Focus groups as moderated discussions can illu-
minate how social and cultural understanding of a speciﬁc
topic evolves through interaction [18].
Data analysis
The discussions in the interview and focus groups were
transcribed verbatim and anonymized; interview citations
(I) show the interview number and respondents age/gender
and examples from focus group discussion (FG) are referred
to only by group/line numbers to protect the identity
of speakers. Transcripts were uploaded into Atlas.ti (ver-
sion 7.0; Scientiﬁc Software Development GmbH, Berlin,
Germany), a qualitative data management and analysis
software. The analysis evolved inductively following the
basic principles of the qualitative content analysis [19].
First, a descriptive coding frame was developed. Coded
segments related to the BSB were compiled in a matrix and
then categorised under themes. The second order coding
was an iterative process to control consistency within and
between the texts. Finally, themes were compared with the
research questions to bring together a valid empirical
summary of key perspectives.
Ethics
The interviews and focus groups were organised in com-
pliance with the Finnish National Board of Research
Integrity principles of ethical review for human sciences
[20]. Since this study did not expose participants to any
major risks or harm, it was considered not to require a
formal ethics approval. Recruitment was designed to ensure
that the participants of the study were properly informed
and participated voluntarily. Interviews were conducted
anonymously. Focus group members signed a consent and
were rewarded with two movie tickets.
Results
Blood bank vs. biobank
The majority of the participants reported having come
across term biobank but described feeling uncertain of its
exact content. Therefore, to start conversations, we gave
everyone a short summary about biobanks in Finland
according to the Biobank Act, including broad consent, and
had a general discussion on their perception of biobank
research. Then we enquired how participants felt about the
plan to set up the Blood Service Biobank (BSB) and if they,
Table 1 Focus group participant information
Focus group (ID) Members (n) Men (n) Women (n) Average age Have donated blood (%)
Helsinki University students (FG1) 6 2 4 21 0
Helsinki University students (FG2) 7 3 4 21 100
The Finnish Defence Force privates (FG3) 7 7 0 20 29
The Finnish Defence Force privates (FG4) 8 6 2 21 50
Frequent blood donorsa (FG5) 6 3 3 40 100
Frequent blood donorsa (FG6) 9 5 4 48 100
Blood donors in GeneRISK study (FG7) 9 3 6 57 100
Blood donors in GeneRISK study (FG8) 6 4 2 58 83
Blood donors in GeneRISK study (FG9) 4 2 2 56 100
Blood donors in GeneRISK study (FG10) 6 4 2 63 100
Total 68 39 29 41 76
aWhole blood donation times ≥7
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as blood donors, would be willing to join the BSB by giving
a blood sample for this purpose.
Apart from very few exceptions, the participants held a
positive attitude towards joining the BSB (Table 2: Quotes
1–2). They saw no problem in combining blood donation
with biobank collection to advance medical research for
better treatments. Giving a blood sample also for the BSB
seemed: “[…] on the ﬁrst reﬂection, to fall in the same
category as blood donation” (FG4: 329–331), constituting a
sensible personal investment in improving public health
care. The BSB was regarded as offering donors an addi-
tional opportunity to help others, since contributions to
medical research could beneﬁt social wellbeing. The cost
and risks of giving an extra sample of blood seemed rela-
tively low to blood donors. From a wider perspective, the
FRC Blood Service was thought to hold the capacity to
collect genetic and other health research material. (Table 2:
Quotes 3–5).
As the discussions progressed, participants concluded
that the process of donating to the BSB was, however, not
equivalent to the donation of blood for immediate needs of
the patients. During the discussion, the participants often
became increasingly aware of the fact that the right to
access and use the donor’s genetic, health and lifestyle data,
rather than the blood in itself, was the focus of the biobank
collection. As donors to the BSB they would share poten-
tially sensitive information—and in case of genetic infor-
mation, data on their relatives as well—and make it
available for research for an unspeciﬁed period of time and
purpose. (Table 2: Quotes 5–6). Unlike blood at the blood
bank that was considered only for the treatment of hospital
patients, the data stored in the biobank seemed to offer
multiple possible future applications. When discussing
donating in the biobank context, participants had to address
the challenge of identifying the future beneﬁciaries of
research. Consideration of the uncertainty regarding bio-
bank donations provoked both high hopes on social beneﬁts
and cautious reminders about ethical risks involved in
allowing valuable data to be used for the wrong ends.
Not everyone was prepared to hand over the rights to
their health information for unspeciﬁed purposes. If nothing
else, the decision required the participants to re-evaluate
their expectations regarding the capability of the organisa-
tion to manage donors’ data; whether or not the organisation
was able to protect their identity and safeguard the data
against unauthorised access. They accepted sharing their
data because it would only be used for beneﬁcial scientiﬁc
projects that meet the requirements set by laws and ethical
standards (Table 2: Quote 7–8), hence, transparency on the
part of the BSB was also regarded as important.
Consent was often described to be an important point in
the process where the voluntary donor should be made
aware of these risks but also of the social value of the
donation. Most of our study participants took it for granted
that involving blood donors in research in which they would
remain identiﬁable automatically required their separate
consent and the right to decline and retract (Table 2:
Quote 9–10). Frequent blood donors would also consider
the option of stopping donating blood if the FRC Blood
Service wasted or used the donations in ways that caused
suffering or injustice. Knowing that human life was at stake,
the participants felt conﬁdent that the FRC Blood Service
strived to avoid disturbances to voluntary blood donations.
They regarded failures in data management or research
responsibilities on the part of the BSB as implausible. Yet,
many saw research data collection as a secondary objective
for the blood bank. (Table 2: Quote 11–12).
Donation experience as a positive resource
The choice to donate data to the BSB was also discussed
among the frequently donating donors as a practical matter
in terms of convenience and habits. Experienced blood
donors had the advantage of knowing the process for
donating blood and providing health information at the
Blood Service and they could therefore apply this experi-
ence to biobank participation (Table 3: Quotes 1–2). From
the point of view of a frequent blood donor, the idea of
integrating research data collection into blood collection
appeared a convenient solution and an effective way to
organise biobank participation. However, some frequent
donors expressed concern about integrating voluntary blood
donation and BSB recruitment. The discussion was focus-
sed on whether the decision was too complex and personal
to be made in a situation where the person’s primary pur-
pose and focus was on blood donation (Table 3: Quote 3).
However blood donation was often perceived to be a less
problematic context for biobank recruitment because it is a
voluntary activity (Table 3: Quote 4).
Reputation and trustworthiness
Despite the new kinds of uncertainties with regard to the
donation of biobank data, the participants were generally
willing to join the BSB because they trusted the Blood
Service—and the welfare institutions it served—to ensure
good social outcomes and to protect donors and their data.
Yet the trust was not granted without reasoning; instead
participants used different indicators to estimate whether the
Blood Service was trustworthy in the context of biobank
donations (Table 4: Quotes1–3). The Blood Service’s public
reputation appeared to be based on history of good perfor-
mance. For many, being part of the Finnish Red Cross
signalled accountability. A voluntary charity should guar-
antee stability and ensure that humanitarian values will not
become subordinate to political and ﬁnancial gains.
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For blood donors who visited the FRC Blood Service
frequently, trust was also a result of positive experiences
from their encounters with the Blood Service. Nurses who
organise the entire donation process with the donors had
an important role in assisting, caring for and offering
information to the donors. Their professional performance
was central in ensuring that the blood donation was
experienced as the “easy” and low-risk experience that the
frequent donors described it to be. Those things that fre-
quent blood donors saw as signs of consideration for their
wellbeing and best interests, e.g., haemoglobin tests and
information provision, were fundamental in building trust.
They were regarded as evidence of the Blood Service’s
commitment to cooperation. (Table 4: Quotes 4–5). The
participants expected that the same norms of care and
reciprocity would also be applied to the new form of
cooperation with the BSB. However, trust was not
equivalent to uncritical acceptance. A scenario that wor-
ried the participants was that the BSB intended to treat
their voluntary donations as a business opportunity. By
choosing commercial proﬁt as its goal, the organisation
would exploit the solidarity of blood donors. (Table 4:
Quote 8–9). According to the Finnish biobank law, the
biobanks must grant appropriate third parties the right to
Table 2 Quotes illustrating theme "Blood bank vs. biobank"
Quote number Interview (I) ID/Focus group
(FG) ID
Citatations from study participants (P)
1 I:22M47 P: Well, it’s ﬁne with me. It is like if you are ready to have an organ-donor card or something
like that, it is not any more strange idea to have a drop of blood stashed somewhere, all the same
2 I:7F50 P: I think that it is a good thing; I don’t ﬁnd it threatening or something that could be misused.
At least I believe that it would be quite a good thing
3 I:15M25 P: That seems quite practical, it would be easy to collect it there. Likely many people would
donate for it, so that there could be a good amount of data in safe
4 FG6: 457–471 P: So if those biobanks already exist, why make one more? Somehow I feel that if all that is
known about me would be there in one pile in some cloud, so then if someone who needs that
information then they would get it from there. Whether that would be FRC [the Finnish Red
Cross, VR] or health care services or who damn ever, I would think it would be clearer than
having a biobank here and there, and little bit of this information about me here, and then some
other thing there
5 I38F28 P: It [the Biobank, VR] sounds modern, I mean good because when there is system like that
when totally new diseases appear then there is some material to at least start researching
6 FG2: 444–448 P1: If many individual things about me are then put together, it comes to mind, that it becomes
more possible that someone might use that for their beneﬁt. Something that I did not intend
when I have wanted to take part, wanted to help in some scientiﬁc research
P2: What does it mean, that some random researcher somewhere knows more about your life
than you do, like, know that you are going to buy food X or to do this...
7 FG5: 408–414 P1: For me it is, that at least it [data, VR] is sufﬁciently protected, whatever that might mean.
That no hacker cannot get in. But it is just that I do not understand these things
P2: And then those people who operate the biobank, the staff, they need to be educated to know
what can be done with it
8 I:137F21 P: Well in principle I would be prepared to give my data, but I would want to be informed each
time before some research that for what purpose it’s used. That what kind of research my data is
being used at. I think it sounds good that it is possible to withdraw if it feels that the research
does not ﬁt with my values somehow
9 I:51F26 P: Of course, when you say it is voluntary so that everyone can make their own decision
whether to take part or not. I don’t see any bigger problem there then
10 FG1: 579–580 P: Isn’t it the basic right of any research participant to know where the sample goes, if one
takes part?
11 I:39F53 P: It might be a good organisation to take care of it [the Biobank, VR]. There has been talk
about resources regarding place and personnel and this eternal saving and rationalisation. So if
this kind of addition might bring something that might help the basic operation to keep in better
strength. So I would see that a positive thing
12 FG3: 434–440 P: It would be a shame if blood donation would become proﬁled as research; that’s unlikely to
happen, but if it would, I would see that as a bad thing (…) Because for me, and perhaps many,
the value in that activity [blood donation, VR] and why to continue is that it can really,
concretely help a person. If it changes into some kind of research centre, some might lose their
motivation because the focus is no longer in helping sick people and there is some research on
the side. I think it would be important to keep the focus on helping patients
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use the data in the biobank; this brought up new questions
about commercialisation and data ownership. (Table 4:
Quotes 6–8). Participants were not generally against
involvement of the private sector where they recognised
potential social beneﬁts, but they thought that selling
blood for proﬁt or handing donor data to private owner-
ship was against blood donors’ intent, hence, a serious
breach of trust. Conversations between donors who
opposed commercial involvement and those who accepted
or allowed it did not always result in a consensus.
Discussion
According to previous studies, participation in genetic
research and biobanks is strongly inﬂuenced by the way a
potential participant interprets the social and institutional
context of the request to donate [8, 12, 14, 21]. The Eur-
opeans are likely to face a complexity of contexts and
varied purposes for which donation of tissue and data are
requested [17]. In the present study, we investigated views
of potential and frequent blood donors on blood donation as
the context for scientiﬁc research and biobanking. We col-
lected data from 61 interviews with current blood donors
and 10 discussion groups consisting of people with and
without practical experience of blood donation. The aim
was to see how shared understanding on voluntary blood
donation as a long-standing national institution and having
practical experience from the Blood Service steered their
views on biobank participation. All participants were asked
to reﬂect on the scenario in which they would be asked
during ‘standard’ blood donation to give a sample and
broad consent for health information to the BSB. The
principles of biobank participation were explained accord-
ing to the Finnish Biobank Act. We found that placing the
biobank within the Blood Service was mostly considered a
good idea, which made the thought of biobank participation
more acceptable for those who were already blood donors.
In general, being able to consider biobanking against the
more familiar institutional context of blood donation helped
participants to construct a more concrete view of partici-
pation. Ideas about and especially personal experience from
blood donation enabled them to adapt to, but also critically
evaluate, the difference between giving blood to patients
and sharing personal data with research. Our study also
identiﬁed three main themes in the discussions on biobank
participation in the blood donation context. These were
similar to those found in previous studies on willingness to
take part in genetic research through biobanking: (i) belief
that biobanks contribute to the public beneﬁt [9, 22], (ii)
perception of the convenience of donation [23], and (iii)
trust [8, 23, 24]. With a systematic qualitative analysis, we
were able to further explore the contextual meaning of these
themes to blood donors and identify supporting arguments
for biobank participation more generally. However, our
method did not allow us to test the prevalence of the
viewpoints within or between populations or to estimate
how widespread they were.
Table 3 Quotes illustrating theme "Donation experience as a positive resource"
Quote number Interview (I) ID/Focus group
(FG) ID
Quotes from study participants (P)
1 FG6: 397–399 P: For me it depends a lot about the type [of donation, VR]: if it is some particular day or two
days a week when the Blood Service is open then I could go donate that sample, why not
2 I:31M18 P: In practise, it could be done at the same time when you are normally donating blood. That
one could, some part [of blood, VR] would just go there. I don’t see any problem with that
3 FG5: 426:446 P1: Now it’s so ﬂuent, easy that you go there, haemoglobin, hand straight and off you go. If
every patient would have that explanation that would you join the biobank, what is biobank,
what does it mean, that wouldn’t be practical. Plus there would be that feeling that if you don’t
want to do it could be difﬁcult to say that I just want to donate blood. Would someone think not
to go donate, if every time someone asks about the biobank, I don’t know. It just isn’t very easy
decision for everyone, I thin, that biobanking
P2: They are two different things, after all, [blood] donation and then research
P1: One blood sample, one syringe gets taken there and then forward, but it is not the sampling
that is most important there, but what happens to the sample afterwards and what impact does
it have
P3: It might really increase the threshold for some, that biobank there, that I cannot go, takes too
much time at there
4 FG6: 623–629 P1: Better be on the safer side there, so that it really is consent from the donor, so that it is not
asked by passing in there, with small…
P2: Yes, or it would be in small writing that if you do not deny then…
P3: If you are in the hospital not in the best shape and then in those conditions you are being
asked different kinds of questions then you not on your sharpest: did you really understand what
was asked, what for did you give your consent
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We found that the experience of blood donation provided
frequent donors with a framework for envisioning what
biobank participation could mean in practice and in relation
to the values they were volunteering for. Often formal
biobank materials offer important technical and legal
information on the purpose of biobanking activities but may
not give straightforward answers to more pragmatic and
moral questions that are of contextual nature [13, 14, 25].
These questions were at the centre of our study: What kind
of experience will a biobank participation be? How to make
sure that one’s contribution to biobank research will
increase, not decrease, wellbeing? Using blood donation as
a benchmark for biobank donation helped donors to assess
whether participation in the BSB was acceptable or a good
choice for them. Understanding of blood donation provided
a comparative viewpoint for deliberations on such questions
and also allowed constructive criticism related to the chal-
lenges of the arrangement. However, integrating biobank
recruitment into the familiar blood bank context could, for
some frequent donors, result in the blurring of the line
between giving blood to transfusion patients and sharing
personal data with researchers that could involve risks
Table 4 Quotes illustrating theme “Reputation and trustworthiness”
Quote number Interview (I) ID /Focus group
(FG) ID
Quotes from participants (P)
1 I:11F51 P: I do trust that in country like Finland studies are made with high professional ethics and
minding the patient so that never to take too much blood or any cells. I do not believe there is
any risks for the research participant (…) No it came to mind all things like sleep apnea that
has been caught from some pills, and (laughs). But no, I do trust that study participants are
well taken care of and research is done in the limits of what people endure
2 I:14F23 P: Well that [the Blood Service, VR] must sound the most trustworthy I personally can think
of. So that I would have a positive view on that [the BSB, VR]
3 FG6: 351–355 P: So if we think what kind of trust Finnish people have towards the FRC [the Finnish Red
Cross, VR] and that if the FRC starts doing something like this, that immediately feels like it
does not need to be questioned so that why not give [consent, VR]
4 I:35TuM27 P: Wouldn’t that be a natural extension, if those [biobanks, VR] are anyway being
established that this would be straight under the Blood Service’s own control
5 FG6: 407–414 P1: This event [focus group discussion, VR] in itself is some kind of proof that whatever
those blood suckers suggest, we are ready to go for it; that our trust is so strong
P2: When I got this invitation, I was with my husband. We quite rarely donate together, but
that was one occasion. And then when I was given this note, my husband was like “I didn’t
get, why I didn’t get”
P1: But also hunger takes people into many situations...
P3: That’s another thing, where ever there is coffee to serve (laughs)
6 FG1:577–579 P: It would be nice to have that kind thing that if there comes a company and gives a little
money and says that lets’ take a blood sample, then those who control the data sends to the
person who owns the blood sample this information as would you like to give your blood to
this study or will you deny it. That there would be something like that. But on the other hand
it only extends these processes and then people anyway say yes or no
7 FG3:334–338 P1: Also I don’t see it to be really realistic, but if suddenly it would turn out that there is a
patent owned by one company who knows how many decades and that blocks some poorer
people to get the treament
P2: Yeah. But I don’t see that this would be a problem about the Blood Service Biobank.
That is the problem of international patenting system. That same case works anywhere. I
think making information available i valuable as such, regarldes of its use. I don’t think that
much harm can be made out of it. Of course if someone started developing some bioweapons
that would be kind of an extreme negative case. That I would not want to happen. But I don’t
see that is a realistic fear
8 FG2: 430–436 P1: Well I would began feeling anxious at the point if my personal data started appear live in
some register
P2: But that’s more something like Google’s rather than the Blood Service’s business
9 FG9:353–355 P: Well let’s put it in this way that I have some study background, so that the future in which
this biobank data could be used for something [bad] like that is still so far away. That I don’t
see that would be a reason, but of course…Like I previously said that I trust the Blood
Service, that kind of retains that I would not believe that the world would change so much
that the Blood Service would become an organisation that would do business with that data.
Or that it would be misused or I believe that kind of future is still likely to be very far away
from our lifetime
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related to data control. To promote blood donors’ will-
ingness to participate, the biobank should take seriously
their wish to see a concrete link between research donations
and welfare beneﬁts for patients [11]. Lack of transparency
could backﬁre if blood donors later felt that their goodwill
or ﬂexibility was exploited.
Building trustworthiness
We found that frequent blood donors were mostly opti-
mistic about the beneﬁts of contributing data to the BSB.
Cooperation with the biobank was also recognised to
require trust to mitigate the uncertainty and risks involved in
such a project [26]. Trust has been shown to be a require-
ment for donors’ willingness to take part in biobanking
[23, 24]. However, trust has been proven difﬁcult to oper-
ationalise on a practical level [26]. When exploring how
blood donors came to deﬁne trustworthiness in relation to
biobanking in the context of voluntary blood donation, we
found three dimensions. We believe these could be of use in
developing public engagement more generally also beyond
this speciﬁc context.
Institutional trust
Biobank participation and broad consent seem to correlate
positively with institutional trust [8, 21, 27]. The general
public tends to view biobanks as a public good [22] and to
favour governance structure independent of commercial or
state control. From the viewpoint of donors, this setting
offers the best way to guarantee that beneﬁts are publicly
shared [28]. For blood donors, the Blood Service provided a
context in which it seemed realistic to assume that positive
outcomes of the biobank donation would outweigh the risk.
As a not-for-proﬁt, well-recognised organisation serving the
public health care, the Blood Service was considered to be a
suitable candidate to host a biobank. The Blood Service,
depending on voluntary support, seemed to anchor also the
BSB into charitable values and transparency with regard to
its goals. Transparency was important since some level of
commercialisation seems inevitable in connection with
biobanking. Commercialisation is likely to remain a con-
tested topic among blood donors who saw that their values
in volunteering conﬂicted with private proﬁt gains.
Investing in donor experience
We found that familiarity that was based on positive
experiences of the Blood Service helped frequent blood
donors to accept participation in the BSB. We know from
previous studies that donors often do not carefully read the
full formal information about biobanking or genetic
research given to them but rather rely on contextual clues of
trustworthiness [14, 21]. There is also evidence that famil-
iarity with biobanking through some previous engagement
[8], and feeling comfortable with the idea of donating blood
and DNA increases willingness to give broad consent to the
biobank [23]. We noted how frequent blood donors eval-
uated trustworthiness through the practices in caring for the
donors and the minimisation of risks: e.g. health tests, the
expert guidance by nurses, and even the refreshments pro-
vided. The threshold for frequent donors to donate more
blood or give more detailed information to the Blood Ser-
vice was low when the process was perceived as a low-risk,
low-cost, and rewarding way of making a positive con-
tribution—also for research [11]. Blood services around the
world invest heavily in donor satisfaction [15]. In turn,
blood donor biobanks recognise that one of their main
assets is the loyal base of healthy donors who are willing to
come frequently to donate blood [2, 5].
Maintaining dialogue with donors
Both biobanks and blood banks rely on public support
[15, 22]. Studies show that to gain and retain participants’
support, biobanks need to learn how best to communicate
the beneﬁts of biobank research to the community. Bio-
banks should also try to address people’s concerns about
biobanking [27] and acknowledge their wish to participate
in discussion on how their samples are used [9]. Commu-
nity engagement is a dialogic process to learn about the
interests of participants and to engage them in developing
better practices [24]. Reasoned debate has been shown to
contribute to achieving public acceptance for contested
aspects of biobanking, such as commercialisation [28].
Exchanging information not only increases conﬁdence, but
reciprocity signals mutual respect between researchers and
participants and valuing of donors’ contribution [11, 29].
Blood banks have systematically promoted public under-
standing of the beneﬁts of blood donation and have been
successful in creating culture speciﬁc discourses that reso-
nate with moral views [15]. This might make them well
positioned to advocate an ethical discussion on biobanking
[1]. Our blood donors reported having learned to appreciate
the importance of blood donation, while they saw them-
selves as being in a process of discussing and learning more
about biobank principles and beneﬁciaries of which they
expected to hear more from the BSB.
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